|
|||||
|
|
Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase |
|
| Authors: | Annie Guérin Lei Chen Raluca Ionescu-Ittu Maryna Marynchenko Roy Nitulescu Robert Hiscock |
| Affiliation: | 1. Analysis Group Inc.Montreal, QCCanada;2. Novartis Pharmaceuticals CorporationEast Hanover, NJUSA;3. Analysis Group Inc.Boston, MAUSA |
| Abstract: | |
| Keywords: | Adverse effects Imatinib Myelogenous leukemia, chronic Nilotinib Quality of life |